

References and Suggested Readings

- Awad MM, Oxnard GR, Jackman DM, et al. MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression. *J Clin Oncol*. 2016;34(7):721-730.
- Camidge DR, Ou SI, Shapiro G, et al. Efficacy and safety of crizotinib in patients with advanced c-MET-amplified non-small cell lung cancer (NSCLC). Abstract 8001. Presented at the American Society of Clinical Oncology Annual Meeting; May 29 – June 3, 2014; Chicago, Illinois.
- Drilon A, Clark JW, Weiss J, et al. Antitumor activity of crizotinib in lung cancers harboring a MET exon 14 alteration. *Nat Med*. 2020;26(1):47-51.
- Drilon A. MET Exon 14 Alterations in Lung Cancer: Exon Skipping Extends Half-Life. *Clin Cancer Res*. 2016 Jun 15;22(12):2832-4.
- Drilon AE, Sima CS, Somwar R, et al. Phase II study of cabozantinib for patients with advanced RET-rearranged lung cancers. Abstract 8007. Presented at the American Society of Clinical Oncology Annual Meeting; May 29 – June 2, 2015; Chicago, Illinois.
- Gainor JF, Curigliano G, Kim D, et al. Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). Abstract 9515. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Gatzemeier U, Groth G, Butts C, et al. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. *Ann Oncol*. 2004;15(1):19-27.
- Goto K, Oxnard GR, Tan DS, et al. Selpercatinib (LOXO-292) in patients with RET-fusion+ non-small cell lung cancer. Abstract 3584. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Heymach J, Negrao M, Robichaux J, et al. A phase II trial of poziotinib in EGFR and HER2 exon 20 mutant non-small cell lung cancer (NSCLC). Abstract OA02.06. Presented at the ISLAC 19th World Conference on Lung Cancer; September 23 – 26, 2018; Toronto, Canada.
- Hida T, Velcheti V, Reckamp KL, et al. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma. *Lung Cancer*. 2019;138:124-130.
- Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. *Ann Oncol*. 2015;26(7):1421-1427.
- Lai WV, Lebas L, Milia J, et al. Afatinib in patients with metastatic HER2-mutant lung cancers: an international multicenter study. Abstract 9071. Presented at the American Society of Clinical Oncology Annual Meeting; June 2 – June 6, 2017; Chicago, Illinois.
- Li BT, Shen R, Buonocore D, et al. Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial. *J Clin Oncol*. 2018;36(24):2532-2537.
- Moro-Sibilot D, Cozic N, Perol M, et al. Activity of crizotinib in MET or ROS1 positive (+) NSCLC: Results of the AcSe Trial. Abstract OA12.03. Presented at the ISLAC 19th World Conference on Lung Cancer; September 23 – 26, 2018; Toronto, Canada.

- Paik PK, Felip E, Veillon R, et al. Tepotinib in Non-Small-Cell Lung Cancer with *MET* Exon 14 Skipping Mutations. *N Engl J Med*. 2020;383(10):931-943.
- Paik PK, Veillon R, Cortot AB, et al. Phase II study of tepotinib in NSCLC patients with METex14 mutations. Abstract 9005. Presented at the American Society of Clinical Oncology Annual Meeting; May 31 – June 4, 2019; Chicago, Illinois.
- Pao W, Hutchinson KE. Chipping away at the lung cancer genome. *Nat Med*. 2012;18(3):349-351.
- Papadimitrakopoulou V, Wu YL, Ahn M, et al. Randomised phase III study of osimertinib vs platinum-pemetrexed for EGFR T790M-positive advanced NSCLC (AURA3). Abstract PL0.03. Presented at the ISLAC 17th World Conference on Lung Cancer; December 4 – 7, 2016.
- Pillai RN, Behera M, Berry LD, et al. HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. *Cancer*. 2017;123(21):4099-4105.
- Seto T, Yoh K, Satouchi M, et al. A phase II open-label single-arm study of vandetanib in patients with advanced RET-rearranged non-small cell lung cancer (NSCLC): Luret study. Abstract 9012. Presented at the American Society of Clinical Oncology Annual Meeting; June 3 – 7, 2016; Chicago, Illinois.
- Smit EF, Nakagawa K, Nagasaka M, et al. Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): interim results of DESTINY-Lung01. Abstract 9504. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Solomon BJ, Mok T, Kim DW, et al; PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. *N Engl J Med*. 2014;371(23):2167-2177.
- Subbiah V, Hu MI, Gainor JF, et al. Clinical activity of the RET inhibitor pralsetinib (BLU-667) in patients with RET fusion+ solid tumors. Abstract 109. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Wang R, Hu H, Pan Y, et al. RET fusions define a unique molecular and clinicopathologic subtype of non-small-cell lung cancer. *J Clin Oncol*. 2012;30(35):4352-4359.
- Wang Y, Jiang T, Qin Z, et al. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib. *Ann Oncol*. 2019;30(3):447-455.
- Wolf J, Overbeck TR, Han J, et al. Capmatinib in patients with high-level MET-amplified non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Abstract 9509. Presented at the 2020 ASCO Virtual Scientific Program. May 29 – June 2, 2020.
- Wolf J, Seto T, Han J, et al. Capmatinib (INC280) in METex14-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Abstract 9004. Presented at the American Society of Clinical Oncology Annual Meeting; May 31 – June 4, 2019; Chicago, Illinois.